Companies Flocking to Japan for Biotech Deals: CJ Partners’ Colin Lee Novick

For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. For The Life Sciences Report Tokyo-based Colin Lee Novick, Managing Director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead.

View the full transcript via The Life Sciences Report here.